A Randomized, Open-label, Single Dose, Two-way Crossover Clinical Trial to Investigate the Pharmacokinetics, Safety, and Tolerability of the Combination of Gemigliptin/Rosuvastatin 50/20 mg in Comparison to Each Component Gemigliptin 50 mg and Rosuvastatin 20 mg Administered in Healthy Male Volunteers

Trial Profile

A Randomized, Open-label, Single Dose, Two-way Crossover Clinical Trial to Investigate the Pharmacokinetics, Safety, and Tolerability of the Combination of Gemigliptin/Rosuvastatin 50/20 mg in Comparison to Each Component Gemigliptin 50 mg and Rosuvastatin 20 mg Administered in Healthy Male Volunteers

Recruiting
Phase of Trial: Phase I

Latest Information Update: 18 Mar 2017

At a glance

  • Drugs Gemigliptin/rosuvastatin (Primary) ; Gemigliptin; Rosuvastatin
  • Indications Dyslipidaemias; Type 2 diabetes mellitus
  • Focus Pharmacokinetics
  • Sponsors LG Life Sciences
  • Most Recent Events

    • 18 Mar 2017 Results presented at the 118th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
    • 10 May 2016 Planned End Date changed from 1 Aug 2016 to 1 Jun 2016.
    • 10 May 2016 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top